Section of Medicine
Chairman: Professor Stan Kaye
The Section of Medicine has three major spheres of activity:
- Joint responsibility (with the Cancer Research UK Centre for Cancer Therapeutics) for the Drug Development Unit, based at the Royal Marsden Hospital, Sutton. The clinical facility is housed in Oak Ward, and the total staff is more than 50. The Unit sees over 500 patients per year for new drug treatment, and with over 20 open trials at any one time it is one of the largest such units in the world
- A translational research programme, in conjunction with the Drug Development Unit, focusing on identifying cancer biomarkers in the context of new drug evaluation. This is co-led by Dr George Thomas and Dr Johann de Bono, who also has a specific interest in prostate cancer (utilising circulating tumour cells).
- A laboratory programme focused on drug discovery and development in ovarian cancer. Professor Ann Jackman leads the team evaluating alpha folate receptor targeted agents, and in conjunction with Professor Stan Kaye, Professor Bob Brown (joint appointment with Imperial College) leads a team aiming to identify new forms of epigenetic therapy in the context of drug resistant disease.
- An integrative programme of core clinical fellows, linking the Section of Medicine to other ICR Sections. These comprise clinical fellows in ovarian cancer drug development (supervised by Professor Kaye, Dr Udai Banerji and Professor Paul Workman of the CRUK Section of Cancer Therapeutics); and in prostate cancer (supervised by Dr Johann de Bono and Professor Colin Cooper in the Prostate Collaborative).
In the Section of Medicine
Team Leader: Dr Johann de Bono
Team Leader: Professor Ann Jackman
Team Leader: Professor Robert Brown